|
**Overview**: ToRCH Panel Avidity IgG**Introduction**: The ToRCH Panel Avidity IgG is a diagnostic tool designed for congenital infection screening using serum samples. In India, ToRCH infections (Toxoplasma, Rubella, CMV, HSV) cause ~5-10 percent of congenital anomalies/miscarriages (Toxoplasma ~10-20 percent seropositivity, CMV ~80-90 percent, Rubella declining post-vaccination), with primary infection in pregnancy leading to fetal defects (microcephaly, deafness, chorioretinitis). High morbidity from under-testing in rural/low-SES pregnant women, limited avidity labs, delayed counseling or termination leading to birth defects or stillbirth. Per obstetrics practices aligned with ICMR, FOGSI, and National Health Mission guidelines, the test employs immunoassay for Toxoplasma, Rubella, and CMV IgG avidity over 1â€"2 days with high accuracy, valuable for dating primary infection (low avidity <30-40 percent indicates recent <3-4 months). This diagnostic falls under infectious disease screening and targets pregnant women with positive IgG/IgM or fetal anomalies, addressing accurate detection to guide reassurance (high avidity = past infection) or intervention. With elevated morbidity due to underdiagnosis, the test supports public health efforts by enabling precise timing of ToRCH exposure and reducing congenital infection burden. Its serum-based approach ensures reliable avidity differentiation.**Other Names**: TORCH Avid IgG Pnl.**FDA Status**: FDA approved, CLIA certified for biochemistry/immunology/clinical pathology, compliant with 2025 standards.**Historical Milestone**: IgG avidity testing standard for ToRCH dating; in India, integrated in high-risk antenatal care.**Purpose**: The test assesses 3 parameters including Toxoplasma IgG Avidity to guide congenital infection screening, date primary exposure, inform counseling.**Test Parameters**: 1. Toxoplasma IgG Avidity, 2. Rubella IgG Avidity, 3. CMV IgG Avidity.**Pretest Condition**: No fasting required; patients should be pregnant with positive IgG/IgM.**Specimen**: 3 mL serum in 1 SST, transported within specified times to maintain sample viability.**Sample Stability at Room Temperature**: 8 hours with proper handling to preserve antibody integrity, ensuring reliable test performance.**Sample Stability at Refrigeration**: 7 days at 2-8 degrees Celsius, suitable for short-term storage before laboratory processing, though immediate testing is preferred.**Sample Stability at Frozen**: 6 months at -20 degrees Celsius, allowing long-term storage for retesting, though freezing may affect some analytes.**Medical History**: Patients should provide details on gestational age, fever/rash history.**Consent**: Written informed consent is required, detailing the test's purpose, potential risks of recent infection including fetal defects, benefits of avidity testing, and minimal discomfort from venipuncture.**Procedural Considerations**: The test involves sample processing using immunoassay by trained personnel to ensure sterile technique, avoid hemolysis, and calculate avidity within 1â€"2 days using provided controls. Laboratories must maintain a controlled environment, adhere to quality assurance protocols.**Factors Affecting Result Accuracy**: Delays beyond stability periods, improper storage conditions, hemolysis can affect results. Correlation with clinical evaluation or additional testing is recommended to confirm findings.**Clinical Significance**: Low avidity indicates recent primary infection (high fetal risk), necessitating specialist input.**Specialist Consultation**: Fetal medicine specialists or obstetricians should be consulted for management.**Additional Supporting Tests**: IgM, PCR on amniotic fluid for confirmation.**Test Limitations**: Avidity interpretation gestation-dependent; comprehensive approach required.**References**: Indian Journal of Obstetrics and Gynaecology 2024, TORCH Studies India 2023. |
